Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS gets support for improving university access and success in South Africa
2013-10-24

 

Members of the SASSE Research team are from left: Carike Jordaan, Dr Francois Strydom, Lana Swart, Seisho Gaboutlwelweboutlwelwakemo, Michael Henn en Katleho Nyaile.
Photo: Supplied
24 October 2013

The university’s Centre of Teaching and Learning (CTL) received a grant for US$820 000 (about R8 million) from the Kresge Foundation for their South African Survey of Student Engagement (SASSE) research team.

The SASSE research team is committed to furthering student access with success by promoting quality teaching and learning institutionally and promoting collective impact around student success nationally.

Through this three-year project, the SASSE team aims to provide a range of deeply contextualised and globally benchmarked student engagement measures that can be used at institutional and module/course level for the South African context. The data from these measures can be used to improve the quality of undergraduate teaching and learning, and participating institutions will have access to appropriate capacity development interventions to empower them to use the data to promote evidence-based change in their institutions.

Dr Francois Strydom, Academic Director at the CTL, says the lessons from this higher-education project could be used to develop a stronger post-school sector which could help the country to deal with the massive challenge of youth unemployment; thereby promoting equity, social justice and a prosperous democracy in South Africa.

The Kresge Foundation is a private philanthropic foundation in the United States, which is focused on creating opportunity for low-income people through various programmes. This three-year project forms part of the Kresge Foundation’s Education Programme, which focuses on promoting access and success at South African universities. Therefore the SASSE project aims to contribute to the Kresge-sponsored Access and Success in Higher Education in South Africa (ASHESA), to promote a national conversation on improving student success.

In January this year, the university was one of four South African universities selected to take part in a multi-million rand programme to bolster private fund-raising and advancement efforts. For this programme the UFS was granted US$640 000 (about R5,6 million) over a period of five years.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept